Enhanced CCR2 expression by ACKR2-deficient NK cells increases tumoricidal cell therapy efficacy

• Published in: Journal of leukocyte biology
• Main Authors: Hayes, Alan J, Pingen, Marieke, Wilson, Gillian, Hansell, Chris, Love, Samantha, Burgoyne, Paul, McElroy, Daniel, Bartolini, Robin, Vidler, Francesca, Schuette, Fabian, Gamble, Alistair, Campbell, Jordan, Galatis, Dimitrios, Campbell, John D M, Graham, Gerard J
• Format: Journal Article
• Language: English
• Published: England 25-07-2024
• Subjects: atypical chemokine receptor; passenger mutation; metastasis
• ISSN: 1938-3673; 1938-3673
• DOI: 10.1093/jleuko/qiae162

Chemokines regulate leukocyte navigation to inflamed sites and specific tissue locales and may therefore be useful for ensuring accurate homing of cell therapeutic products. We, and others, have shown that atypical chemokine receptor 2 (ACKR2), deficient mice (ACKR2-/-) are protected from metastasis development in cell line and spontaneous mouse models. We have shown that this relates to enhanced CCR2 expression on ACKR2-/- NK cells allowing them to home more effectively to CCR2 ligand expressing metastatic deposits. Here we demonstrate that the metastatic-suppression phenotype in ACKR2-/- mice is not a direct effect of the absence of ACKR2. Instead, enhanced NK cell CCR2 expression is caused by passenger-mutations that originate from creation of the ACKR2-/- mouse strain in 129 embryonic stem cells. We further demonstrate that simple selection of CCR2+ NK cells enriches for a population of cells with enhanced anti-metastatic capabilities. Given the widespread expression of CCR2 ligands by tumors, our study highlights CCR2 as a potentially important contributor to NK cell tumoricidal cell therapy.